Navigation Links
Class in Biological Technology

KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid

... Company notified certain owners of the Company's class A and class B Common Stock, as further described below (the ... their beneficial ownership of the Company's class A Common Stock and a Schedule 13D disclosing ...

CuraGen Reports Second Quarter 2009 Financial Results

... of understanding, to settle recent shareholder class action lawsuits filed in the State of Connecticut ... of understanding to settle two shareholder class action lawsuits that had been filed in connection ... with respect to the claims asserted in the class action suits, unfortunately, the monthly costs of ...

Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity

... is defined as BMI 25 to 29.9 kg/m2, Obesity class I is BMI 30 to 34.9 kg/m2, Obesity class II is BMI 35 to 39.9 kg/m2 and Obesity class III is BMI 40 kg/m2 or more. Of the over 100 ...

Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited

... lead programmes are centred around a class of small peptide molecules called lantibiotics, a drug class that, until now, has been underexploited due to ... Lantibiotics are a naturally occurring class of antibiotic peptide compounds found in a large ...

New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance

... that can inhibit effectiveness of newest class of antiretroviral therapy MADISON, N.J., ... of HIV drug resistance will respond to the latest class of HIV antiretroviral therapies. The HIV-1 ... of coreceptor on the cell's surface. The newest class of antiretroviral drugs, called entry inhibitors, ...

Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation

... of GPCRs to disease pathways has resulted in this class of receptors accounting for more than 50 percent ... are the most pharmacologically important class of drug targets, the Tag-lite(TM) technology is a ... clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. ...

Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association

... Germany. Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors ... Carfilzomib Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors. ... lead product, carfilzomib, is the first in a new class of selective, irreversible proteasome inhibitors. ...

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

... evidence of the unsupported extrapolation to the class of the toxicity/benefit correlation in the ... benefit from nimotuzumab as from the rest of the class without the physical, emotional and financial ... the extension of this correlation to the entire class is unsubstantiated," added Dr. Nicacio. The ...

Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting

... Florida. Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors ... Carfilzomib Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors. ... lead product, carfilzomib, is the first in a new class of selective, irreversible proteasome inhibitors. ...

Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator

... IMX942, the first of this truly innovative new class of drugs, in patients at risk of infection; we ... About IMX942 IMX942 is the first of a new class of drugs known as Innate Defense Regulators, ... of the innate immune response. Inimex' first in class products show promise for the safe and effective ...

Roche Madison Moves to New Facility

... certain genes - represents a potential whole new class of therapeutics for difficult to treat diseases. ... in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on ... for many diseases. DPCs represent a first in class polymer-based nanoparticle that allows for ...

Frost & Sullivan Recognizes ApaTech's Leadership in Orthopedic Biologics

... by ApaTech has introduced the revolutionary new class of bone graft substitute called Actifuse, which ... stability. ApaTech's Actifuse is a new class of synthetic bone graft and is an exceptional ... believes that Actifuse is the first of a new class of synthetic bone graft materials that combine ...

aTyr Pharma to Present at ChinaBio(R) Investor Forum in Hong Kong

... on discovery and development of an entirely new class of natural protein therapeutics (biologics) for ... activities, roles and functions for this ancient class of enzymes and reported the first evidence that ... a wide variety of cell signaling activities, this class of unexplored peptides provides a reservoir of ...

Dr. James Cai Joins aTyr Pharma to Drive Clinical Development in Asia

... on discovery and development of an entirely new class of natural protein therapeutics (biologics) for ... activities, roles and functions for this ancient class of enzymes and reported the first evidence that ... a wide variety of cell signaling activities, this class of unexplored peptides provides a reservoir of ...

Mindray Announces 2008 Fourth Quarter and Full Year Results

... shares, which are divided into two classes, class A and class B. Each of our American Depositary Shares, which ... on the New York Stock Exchange, represents one class A ordinary share. About Mindray ...

BioMS Medical warrant extension

... each of which entitles the holder to purchase one class A common share at a price of $5.00 per share, ... 2008, the shareholders holding a majority of the class A common shares, excluding the votes attached to class A common shares held by insiders whose warrants ...

KanekaQH(TM) Ubiquinol Dramatically Boosts Ejection Fraction in Patients With Late-Stage Congestive Heart Failure

... classified as New York Heart Association (NYHA) class IV - a designation that denotes patients' showed ... discomfort. The prognosis for patients with NYHA class IV heart failure is very poor, with mortality ... May of 2007, the clinical trial followed seven class IV patients who were under maximal medical ...

Nature Reviews Publishes Article About Jennerex's Multi-Mechanistic Cancer Therapeutic

... to guide Jennerex toward a completely new class of novel, oncolytic poxviruses, combining ... that products from this breakthrough therapeutic class can systemically target cancers in a highly ... in patients to date put the company's product class in a leadership position. Jennerex's therapeutic ...

Shareholder Class Action Filed Against Elan Corporation, plc by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP

... LLP: Notice is hereby given that a class action lawsuit was filed in the United States ... company. The Complaint alleges that during the class Period the Company made materially false and ... Plaintiff seeks to recover damages on behalf of class members and is represented by the law firm of ...

Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology

... myeloma. Carfilzomib is the first in a new class of specific proteasome inhibitors being developed ... Carfilzomib is the first in a new class of highly specific proteasome inhibitors. ... product, carfilzomib, is the first in a new class of highly specific proteasome inhibitors, and is ...

Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth

... channels. The target goal is to develop 10 class A nation-wide distributors with over $73.5 ... 30% of Tianyin's annual sales, and 100 class B distributors with annual sales between $29.4 ... contribute approximately 40% of annual sales. class C distributors which have annual sales above $7 ...

RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease

... First in class drug illustrates early signal of transport of key ... treatment with its lead drug RVX-208, a first in class ApoA-I/Prebeta-HDL elevating drug, in a ... area." About RVX-208 RVX-208, a first in class novel small molecule therapeutic that facilitates ...

Masimo Reports Third Quarter 2008 Financial Results

... to common stockholders: Net income - two class method (1) $4,985 ... common shares outstanding - two class method 16,704,285 16,654,586 Basic ... income for period during which single class of equity securities was outstanding ...

ARIUS sale approved by shareholders

... with 99.99% of Common Shareholders and class F Warrant holders, voting as a class, and 100% of class G Warrant holders, represented in person or by ... receiving $2.44 per Common Share, holders of class F Warrants receiving $1.44 ...

Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director

... company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today ... Phase II trials, from a proprietary breakthrough class of targeted and armed oncolytic poxviruses. Tumor ... patients to date put the Company's product class in a leadership position. Jennerex's position is ...

Explosion Proof Fluorescent Lights Keep Paint Spray Booths and Oil Rig Workers Safe

... UL certified lights that have an explosion proof class rating, and Magnalight.com now has a significant ... UL certified lights that have an explosion proof class rating. And Magnalight.com now has a significant ... Explosion proof certified lights are typically class 1 Division 1 for Groups C and D, indicating that ...

Microbes, Inc. Extends Warrant Tender Offer

... B Common Stock Purchase Warrants, class 1 and class B Common Stock Purchase Warrants, class 2 until 12:00 midnight, New York City time, ...

Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights

... Genta's submission as a complete response and a class 2 resubmission with a Prescription Drug User Fee ... stock, for a settlement in principle of class action litigation. This liability was marked to ... semi-synthetic taxane that is in the same drug class as paclitaxel and docetaxel. Ganite and ...

WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology

... won the 2008 Frost & Sullivan Award for Best in class Outsourced R&D in Pharmaceuticals ... The Frost & Sullivan Award for Best in class Outsourced R&D in Pharmaceuticals ... advantage, high technical expertise and world class management, robust expanding service portfolio, ...

Infinity Bio-Energy Ltd. Announces 2008 Annual General Meeting

... and Dimitri Marriette Henri Pauwels as class III Directors, and authorize them to ... re-election of John Walter and Dominic DiMarco as class II Directors, and authorize them to ... Lipman and Sergio Thompson-Flores as class II Directors, and authorize them to appoint ...

Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane

... semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. However, ... prominent side- effects of this drug class include myelosuppression (low blood counts) and ... the high antitumor activity of the taxane drug class while eliminating infusion reactions, reducing ...

Notice of Initial Distribution of Net Settlement Funds

... No. 99-CV-20743 RMW (PVT) And Related Cases class ACTION This Document Relates To: ALL ACTIONS. ... (PVT), recently has been made to all Settlement class Members who submitted a Claim to the ... are available to answer questions from Settlement class Members concerning the initial distribution or ...

SynCo Bio Partners Completes Manufacture and Release of ActoGeniX' Lead Product for Phase II Clinical Trials

... and commercialization of ActoBiotics(TM), a novel class of protein-based biopharmaceuticals that can be ... and commercialization of ActoBiotics(TM), a novel class of biopharmaceuticals for the targeted treatment ... the commercial potential of its promising new class of biopharmaceutical products. For more ...

Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance

... million expense related to the settlement of a class action lawsuit in connection with the Company's ... $0.33 per share, based on 250.6 million diluted class A common shares outstanding. In calculating CNI, ... of $326 to $339 million. Using 251.0 million class A common shares, the Company expects CNI per ...

Mindray Medical International Announces First Quarter 2008 Results

... shares, which are divided into two classes, class A and class B. Each of our American Depositary Shares, which ... on the New York Stock Exchange, represents one class A ordinary share. The accounting policies ...

Masimo Reports First Quarter 2008 Financial Results

... to common stockholders: Net income - two class method $9,097 ... average common shares outstanding - two class method 16,592,163 NA ... Net income for period during which single class of equity securities was outstanding ...

Vasogen Announces Implementation of Strategic Restructuring Plan

... Celacade for the treatment of patients with NYHA class II heart failure. Given these delays, ... VP025, the lead product candidate from this new class of drugs, is currently being developed for the ... is an additional product candidate from this new class of drugs, with the potential to treat other ...

Martek Announces Final Judgment and Order of Dismissal in Class Action

... approving the settlement of the consolidated class action brought on behalf of certain purchasers of ... of December 10, 2007, the settlement of the class action calls for a cash payment of $6 million ... that settlement fund will be distributed to class members and all claims against the Company and ...

Vasogen Announces First Quarter 2008 Results

... for the treatment of patients with NYHA class II heart failure. General and administration ... pre-specified subgroup of patients with NYHA class II heart failure who received Celacade therapy, ... with New York Heart Association ("NYHA") class II heart failure. The teleconference with ...

Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round

... company developing Anticalins(R), a novel class of targeted human protein therapeutics, announced ... strategy of developing Anticalins(R) as the next class of biopharmaceutical products. We welcome Michael ... and development of Anticalins(R), a novel class of targeted human proteins designed to diagnose ...
Other Contents
(Date:7/25/2014)... WASHINGTON (July 24, 2014)The link between autism and ... the puzzle of the disease, and is largely ... Foundation Autism Research Initiative (SFARI), George Washington University ... to offer truly integrative and in-depth answers to ... research. , LaMantia, professor of pharmacology and ...
(Date:7/25/2014)... Prediabetes and Diabetes increasingly consume the healthcare ... immediate attention. , To address the ... impacting low-and middle-income countries, global leaders in ... research in diabetes prevention and development of ... important text. , This book on ...
(Date:7/25/2014)... After development of diffusion tensor tractography (DTT), which ... reconstruction and estimation for three motor tracts, such ... the corticoreticular pathway became possible. The corticospinal tract ... for motor function in the human brain. Several ... tract by transtentorial herniation. In addition, some studies ...
Breaking Biology News(10 mins):GW researcher receives grant to answer the how and why of autism during development 2What constitutes an effective response to the global 'diabesity' tsunami? 2
(Date:7/28/2014)... TherapySites, the leading website and ... its affiliation with the Illinois Association for Marriage ... TherapySites to continue to extend their online marketing solutions ... , “There has been a fundamental shift in the ... 3 billion Internet users, it is so important to ...
(Date:7/28/2014)... According to the Heartburn No More PDF review ... will help people get rid of acid reflux ... about heartburn and acid reflux. In addition, inside this book, ... risk factors for reflux disease. , Vkool informs in ... of symptoms of reflux disease naturally without medications. The book ...
(Date:7/28/2014)... New York, NY (PRWEB) July 28, 2014 ... completed the exit of its investment in Loftware, Inc., ... Partners of Boston. Shore Points was the lead investor ... which the Company has become the leading international provider ... applications. , “Loftware has been a great investment for ...
(Date:7/27/2014)... Hyaluronic Acid can hold 1,000 times ... to the power of Hyaluronic Serums. , "Hyaluronic acid ... of Sublime Beauty®. "But like collagen, it diminishes with ... improves skin moisture-retention and radiance." , Hyaluronic acid ... healthy and beautiful look. Key Ingredients in the serum ...
(Date:7/27/2014)... hepatitis E virus (HEV) transmission by blood components indicates ... HEV in their plasma. The findings, published in ... components (eg, red cells, platelets, and fresh frozen plasma) ... , The study retrospectively screened 225 000 individual ... 2012 and Sept, 2013 for HEV RNA. 79 donors ...
Breaking Medicine News(10 mins):Health News:TherapySites (Websites for Therapists) Partners with the Illinois Association for Marriage and Family Therapy 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Shore Points Capital Announces Sale of Portfolio Company Loftware 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2
Other TagsOther Tags